Modulations of fecal microbiota as a risk factor and prognostic quantification for colorectal cancer: a literature review

Authors

  • Bruno Menezes Teixeira Campos Universidade de Vassouras - Univassouras
  • Ana Beatriz de Mello Domingos Universidade de Vassouras - Univassouras
  • Lara Oliveira Holak dos Santos Universidade de Vassouras - Univassouras
  • Bruna Cristina Moreira Santos Universidade de Vassouras - Univassouras
  • Adriana Rodrigues Ferraz Universidade de Vassouras - Univassouras

DOI:

https://doi.org/10.24859/SaberDigital.2025v18n1.1644

Keywords:

Colorectal Neoplasms, Gastrointestinal Microbiome, Diet, Biomarkers, Tumor

Abstract

Introduction: Colorectal cancer (CRC) is a malignant tumor with a high incidence in Brazil, causing significant morbidity, mortality, and public health costs. Cases have been increasing, particularly among young individuals, due to lifestyle factors, especially dietary habits that alter the host's gut microbiota, acting as a carcinogenic factor. Objective: To correlate the microbiota with the incidence of CRC, highlighting diet as both a risk and protective factor, and to explore these microbiological changes as potential tumor biomarkers for screening and prognosis methods. Materials and Methods: A systematic review was conducted using PubMed and the Virtual Health Library with the descriptors “colorectal cancer” and “fecal microbiome.” Publications from the last five years, including controlled clinical trials, observational studies, and full-text articles, were included. Review articles, paid publications, and those outside the proposed theme were excluded. A total of 22 articles were analyzed. Results and Discussion: Through the analyzed studies, it was observed that bacteria such as Fusobacterium nucleatum create a pro-inflammatory environment and affect the carcinogenesis of intestinal cells. Diet was identified as a significant risk factor (e.g., red and processed meats) and a protective factor (e.g., fibers and vegetables), directly affecting inflammatory status. Changes in microbiota composition support its use as CRC biomarkers with potential applicability in diagnostics, treatment evaluation, and effectiveness. Conclusion: Bacteria contribute to CRC development through metaplasia driven by increased virulence associated with diet. Analyzing these bacteria can serve as an efficient tumor biomarker for diagnosis, therapeutic evaluation, and prognosis.

Downloads

Download data is not yet available.

References

AGARWAL, A.; ZHANG, T.; RAVINDRAN, N.; et al. Off-Label Use of Multitarget Stool DNA Testing in Primary Care. The American Journal of Gastroenterology, v. 116, n. 4, p. 829–832, 1 abr. 2021. DOI: https://doi.org/10.14309/ajg.0000000000001143

ASLAM, M. N.; BASSIS, C. M.; BERGIN, I. L.; et al. A Calcium-Rich Multimineral Intervention to Modulate Colonic Microbial Communities and Metabolomic Profiles in Humans: Results from a 90-Day Trial. Cancer Prevention Research, v. 13, n. 1, p. 101–116, jan. 2020. DOI: https://doi.org/10.1158/1940-6207.CAPR-19-0325

BOSCH, S.; ACHARJEE, A.; QURAISHI, M. N.; et al. Integration of stool microbiota, proteome and amino acid profiles to discriminate patients with adenomas and colorectal cancer. Gut microbes, v. 14, n. 1, p. e2139979, nov. 2022. DOI: https://doi.org/10.1080/19490976.2022.2139979

BOSCH, S.; ACHARJEE, A.; QURAISHI, M. N.; et al. The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma. Gut microbes, v. 14, n. 1, p. e2038863, fev. 2022. DOI: https://doi.org/10.1080/19490976.2022.2038863

BUCHER-JOHANNESSEN, C.; BIRKELAND, E.; VINBERG, E.; et al. Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing. Frontiers in Oncology, v. 13, p. e1183039, abr. 2023. DOI: https://doi.org/10.3389/fonc.2023.1183039

ECKMANN, J. D.; EBNER, D. W.; KISIEL, J. B. Multi-Target Stool DNA Testing for Colorectal Cancer Screening: Emerging Learning on Real-world Performance. Current Treatment Options in Gastroenterology, v. 18, n. 1, p. 109–119, jan. 2020. DOI: https://doi.org/10.1007/s11938-020-00271-5

EISELE, Y.; MALLEA, P. M.; GIGIC, B.; et al. Fusobacterium nucleatum and Clinicopathologic Features of Colorectal Cancer: Results From the ColoCare Study. Clinical Colorectal Cancer, , v. 20, n. 3, p. e165–e172, set. 2021. DOI: https://doi.org/10.1016/j.clcc.2021.02.007

FAN, J.Q.; ZHAO, W. F.; LU, Q. W.; et al. Fecal microbial biomarkers combined with multi-target stool DNA test improve diagnostic accuracy for colorectal cancer. World Journal of Gastrointestinal Oncology, v. 15, n. 8, p. 1424–1435, ago. 2023. DOI: https://doi.org/10.4251/wjgo.v15.i8.1424

FARSI, D. N.; GALLEGOS, J. L.; KOUTSIDIS, G.; et al. Substituting meat for mycoprotein reduces genotoxicity and increases the abundance of beneficial microbes in the gut: Mycomeat, a randomised crossover control trial. European Journal of Nutrition, v. 62, n. 3, p. 1479-1492, jan. 2023. DOI: https://doi.org/10.1007/s00394-023-03088-x

FRUGÉ, A. D.; SMITH, K. S.; RIVIERE, A. J.; et al. A Dietary Intervention High in Green Leafy Vegetables Reduces Oxidative DNA Damage in Adults at Increased Risk of Colorectal Cancer: Biological Outcomes of the Randomized Controlled Meat and Three Greens (M3G) Feasibility Trial. Nutrients, v. 13, n. 4, p. 1220, abr. 2021. DOI: https://doi.org/10.3390/nu13041220

HAGHI, F.; GOLI, E.; MIRZAEI, B.; et. al. The association between fecal enterotoxigenic B. fragilis with colorectal cancer. BMC Cancer, v. 19, n. 1, p. 879, set. 2019. DOI: https://doi.org/10.1186/s12885-019-6115-1

INCA - Estatísticas de câncer. Instituto Nacional de Câncer. Ministério da Saúde [Internet]. Distrito Federal. 2022 jun. Disponível em: https://www.gov.br/inca/pt-br/assuntos/cancer/numeros. Acesso em: ago 2023.

JUNG, S. Y.; ZHANG, Z.-F. The effects of genetic variants related to insulin metabolism pathways and the interactions with lifestyles on colorectal cancer risk. Menopause, v. 26, n. 7, p. 771–780, jul. 2019. DOI: https://doi.org/10.1097/GME.0000000000001301

KOSTIC, A. D.; CHUN, E.; ROBERTSON, L.; et al. Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment. Cell Host & Microbe, v. 14, n. 2, p. 207–215, ago. 2013. DOI: https://doi.org/10.1016/j.chom.2013.07.007

LAVELLE, A.; NANCEY, S.; REIMUND, J. M.; et al. Fecal microbiota and bile acids in IBD patients undergoing screening for colorectal cancer. Gut Microbes, v. 14, n. 1, p. e2078620, mai. 2022. DOI: https://doi.org/10.1080/19490976.2022.2078620

LONG, S.; YANG, Y.; SHEN, C.; et al. Metaproteomics characterizes human gut microbiome function in colorectal cancer. npj Biofilms and Microbiomes, v. 6, n. 14, p. 1-10, mar. 2020. DOI: https://doi.org/10.1038/s41522-020-0123-4

MCQUADE, J. L.; DANIEL, C. R.; HELMINK, B. A.; et al. Modulating the microbiome to improve therapeutic response in cancer. The Lancet Oncology, v. 20, n. 2, p. e77–e91, fev. 2019. DOI: https://doi.org/10.1016/S1470-2045(18)30952-5

MIMA, K.; NISHIHARA, R.; QIAN, Z. R.; et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut, v. 65, n. 12, p. 1973–1980, dez. 2016. DOI: https://doi.org/10.1136/gutjnl-2015-310101

OCVIRK, S.; WILSON, A. S.; POSMA, J. M.; et al. A prospective cohort analysis of gut microbial co-metabolism in Alaska Native and rural African people at high and low risk of colorectal cancer. The American Journal of Clinical Nutrition, v. 111, n. 2, p. 406-419, fev. 2020. DOI: https://doi.org/10.1093/ajcn/nqz301

OSMAN, M. A.; NEOH, H.; AB MUTALIB, N. S.; et al. Parvimonas micra, Peptostreptococcus stomatis, Fusobacterium nucleatum and Akkermansia muciniphila as a four-bacteria biomarker panel of colorectal cancer. Scientific Reports, v. 11, n. 1, p. 2925, fev. 2021. DOI: https://doi.org/10.1038/s41598-021-82465-0

RUBINSTEIN, M.; WANG, X.; LIU, W.; et al. Fusobacterium nucleatum Promotes Colorectal Carcinogenesis by Modulating E-Cadherin/β-Catenin Signaling via its FadA Adhesin. Cell Host & Microbe, v. 14, n. 2, p. 195–206, ago. 2013. DOI: https://doi.org/10.1016/j.chom.2013.07.012

RUSSO, E.; GLORIA, L. D.; NANNINI, G.; et al. From adenoma to CRC stages: the oral-gut microbiome axis as a source of potential microbial and metabolic biomarkers of malignancy. Neoplasia (New York, NY), v. 40, p. 100901, 1 jun. 2023. DOI: https://doi.org/10.1016/j.neo.2023.100901

SERRANO, D.; POZZI, C.; GUGLIETTA, S.; et al. Microbiome as Mediator of Diet on Colorectal Cancer Risk: The Role of Vitamin D, Markers of Inflammation and Adipokines. Nutrients, v. 13, n. 2, p. 363, jan. 2021. DOI: https://doi.org/10.3390/nu13020363

SO, W. K. W.; CHAN, J. Y. W.; LAW, B. M. H.; et al. Effects of a Rice Bran Dietary Intervention on the Composition of the Intestinal Microbiota of Adults with a High Risk of Colorectal Cancer: A Pilot Randomised-Controlled Trial. Nutrients, v. 13, n. 2, p. 526, fev. 2021. DOI: https://doi.org/10.3390/nu13020526

SOBHANI, I.; BERGSTEN, E.; COUFFIN, S.; et al. Colorectal cancer-associated microbiota contributes to oncogenic epigenetic signatures. Proceedings of the National Academy of Sciences, v. 116, n. 48, p. 24285–24295, nov. 2019. DOI: https://doi.org/10.1073/pnas.1912129116

TAN, R.; DONG, H.; CHEN, Z.; et al. Intestinal Microbiota Mediates High-Fructose and High-Fat Diets to Induce Chronic Intestinal Inflammation. Frontiers in Cellular and Infection Microbiology, v. 11, p. 654074, jun. 2021. DOI: https://doi.org/10.3389/fcimb.2021.654074

TARALLO, S.; FERRERO, G.; GALLO, G.; et al. Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples. mSystems, v. 4, n. 4, p. e00289-19, out. 2019. DOI: https://doi.org/10.1128/mSystems.00289-19

VAUPEL, P.; HARRISON, L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. The Oncologist, v. 9 Suppl 5, p. 4–9, nov. 2004. DOI: https://doi.org/10.1634/theoncologist.9-90005-4

WANG, D.; MENG, S.; LI, J.; et al. Associations of Adherence to the 2018 World Cancer Research Fund and the American Institute for Cancer Research Dietary Recommendations with Gut Microbiota and Inflammation Levels. Nutrients, v. 15, n. 17, p. 3705–3705, ago. 2023. DOI: https://doi.org/10.3390/nu15173705

WEBER, A.; IBRAHIM, H.; BAXTER, B. A.; et al. Integrated Microbiota and Metabolite Changes following Rice Bran Intake during Murine Inflammatory Colitis-Associated Colon Cancer and in Colorectal Cancer Survivors. Cancers, v. 15, n. 8, p. 2231–2231, abr. 2023. DOI: https://doi.org/10.3390/cancers15082231

WENG, M.T.; CHIU, Y.T.; WEI, P. Y.; et al. Microbiota and gastrointestinal cancer. Journal of the Formosan Medical Association, Taiwan, v. 118 Suppl 1, p. S32–S41, mar. 2019. DOI: https://doi.org/10.1016/j.jfma.2019.01.002

YACHIDA, S.; MIZUTANI, S.; SHIROMA, H.; et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nature Medicine, v. 25, n. 6, p. 968–976, jun. 2019. DOI: https://doi.org/10.1038/s41591-019-0458-7

YANG, Y.; DU, L.; SHI, D.; et al. Dysbiosis of human gut microbiome in young-onset colorectal cancer. Nature Communications, v. 12, n. 1, p. 6757, nov. 2021. DOI: https://doi.org/10.1038/s41467-021-27112-y

YANG. Y.; MISRA, B. B.; LIANG, L.; et al. Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer. Theranostics, v. 9, n. 14, p. 4101–4114, mai. 2019. DOI: https://doi.org/10.7150/thno.35186

ZHANG, Y.; YU, X.; YU, E.; et al. Changes in gut microbiota and plasma inflammatory factors across the stages of colorectal tumorigenesis: a case-control study. BMC Microbiology, v. 18, n. 1, p. 92, ago. 2018. DOI: https://doi.org/10.1186/s12866-018-1232-6

Published

2025-02-03

How to Cite

Menezes Teixeira Campos, B., de Mello Domingos, A. B., Oliveira Holak dos Santos, L. ., Moreira Santos, B. C., & Rodrigues Ferraz, A. (2025). Modulations of fecal microbiota as a risk factor and prognostic quantification for colorectal cancer: a literature review. Revista Saber Digital, 18(1), e20251804. https://doi.org/10.24859/SaberDigital.2025v18n1.1644

Issue

Section

Medicine